Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 34 Issue 4
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2016  >  34(4): 366-371

ZHU Hengmei, LU Guihua, FANG Shuheng, XU Lili. Pain Management with fentanyl transdermal and morphine subcutaneous injection for the patients with advanced liver cancer pain after intervention therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 75-77. doi: 10.3969/j.issn.1006-0111.2017.01.019
Citation: CAO Yue, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 366-371. doi: 10.3969/j.issn.1006-0111.2016.04.022
shu

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

doi: 10.3969/j.issn.1006-0111.2016.04.022
  • 1.

    First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China

  • 2.

    Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • Received Date: 2016-04-08
  • Rev Recd Date: 2016-05-17
  • Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.
  • [1] 陈勇. 口服单药希罗达与FOLFOX方案治疗晚期结直肠癌的疗效比较[J]. 中国药业,2012,21(11):90-91.
    [2] Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (provenge) for prostate cancer[J]. Maturitas,2011,69(4):296-303.
    [3] Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy[J]. J Transl Med,2011,9:214.
    [4] Bol KF, Tel J, de Vries IJM, et al. Naturally circulating dendritic cells to vaccinate cancer patients[J]. Oncoimmunology,2013,2(3):e23431.
    [5] Tel J, Smits EL, Anguille S, et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities[J]. Blood,2012,120(19):3936-3944.
    [6] Wang X, Yu W, Li H, et al. Can the dual-functional capability of CIK cells be used to improve antitumor effects?[J]. Cell Immunol,2014,287(1):18-22.
    [7] Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy[J]. Eur J Cell Biol,2012,91(1):53-58.
    [8] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
    [9] Jakel CE, Hauser S, Rogenhofer S, et al. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma[J]. Clin Dev Immunol,2012,2012:473245.
    [10] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
    [11] Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models[J]. PLoS One,2013,8(6):e65757.
    [12] Hasumi K, Aoki Y, Wantanabe R, et al. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy[J]. Oncoimmunology,2013,2(10):e26381.
    [13] Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells:first report of the international registry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol,2011,137(2):305-310.
    [14] Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:more than one plus one?[J]. Leuk Res,2011,35(9):1136-1142.
    [15] Schlom J. Recent advances in therapeutic cancer vaccines[J]. Cancer Biother Radiopharm,2012,27(1):2-5.
    [16] Marten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells[J]. Haematologica,2001,86(10):1029-1037.
    [17] Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immunotherapy[J]. Discov Med,2013,15(84):301-308.
    [18] Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies[J]. Cancer Control,2013,20(1):32-42.
    [19] Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients[J]. Oncol Lett,2013,6(2):537-541.
    [20] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
    [21] Duru N, Fan M, Candas D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells[J]. Clin Cancer Res,2012,18(24):6634-6647.
    [22] Beutler N, Hauka S, Niepel A, et al. A natural tapasin isoform lacking exon 3 modifies peptide loading complex function[J]. Eur J Immunol,2013,43(6):1459-1469.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0401234Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 89.4 %FULLTEXT: 89.4 %META: 8.4 %META: 8.4 %PDF: 2.2 %PDF: 2.2 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 25.8 %其他: 25.8 %China: 2.0 %China: 2.0 %[]: 0.8 %[]: 0.8 %上海: 1.2 %上海: 1.2 %中卫: 0.4 %中卫: 0.4 %临汾: 0.2 %临汾: 0.2 %丽水: 0.2 %丽水: 0.2 %亳州: 0.2 %亳州: 0.2 %信阳: 0.2 %信阳: 0.2 %兰州: 0.2 %兰州: 0.2 %北京: 17.6 %北京: 17.6 %厦门: 0.2 %厦门: 0.2 %台州: 0.2 %台州: 0.2 %合肥: 0.2 %合肥: 0.2 %呼和浩特: 0.2 %呼和浩特: 0.2 %商洛: 0.2 %商洛: 0.2 %嘉兴: 0.2 %嘉兴: 0.2 %大同: 0.2 %大同: 0.2 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %太原: 0.4 %太原: 0.4 %宁波: 0.2 %宁波: 0.2 %安康: 0.2 %安康: 0.2 %宜昌: 0.2 %宜昌: 0.2 %巴音郭楞: 0.2 %巴音郭楞: 0.2 %广州: 0.2 %广州: 0.2 %廊坊: 0.2 %廊坊: 0.2 %张家口: 1.8 %张家口: 1.8 %恩施: 0.4 %恩施: 0.4 %成都: 0.6 %成都: 0.6 %昆明: 0.4 %昆明: 0.4 %昌吉: 0.2 %昌吉: 0.2 %普洱: 0.2 %普洱: 0.2 %朝阳: 0.2 %朝阳: 0.2 %杭州: 1.0 %杭州: 1.0 %武汉: 0.6 %武汉: 0.6 %沈阳: 0.2 %沈阳: 0.2 %泉州: 0.2 %泉州: 0.2 %泰州: 0.2 %泰州: 0.2 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.8 %济南: 0.8 %淄博: 0.2 %淄博: 0.2 %深圳: 0.4 %深圳: 0.4 %湖州: 0.4 %湖州: 0.4 %湛江: 0.2 %湛江: 0.2 %漳州: 0.4 %漳州: 0.4 %潍坊: 0.6 %潍坊: 0.6 %牡丹江: 0.2 %牡丹江: 0.2 %盐城: 0.4 %盐城: 0.4 %石家庄: 1.0 %石家庄: 1.0 %绍兴: 0.2 %绍兴: 0.2 %芒廷维尤: 12.4 %芒廷维尤: 12.4 %苏州: 0.6 %苏州: 0.6 %莆田: 0.4 %莆田: 0.4 %菏泽: 0.2 %菏泽: 0.2 %衢州: 0.2 %衢州: 0.2 %西宁: 15.2 %西宁: 15.2 %西安: 0.4 %西安: 0.4 %贵阳: 0.2 %贵阳: 0.2 %运城: 0.4 %运城: 0.4 %重庆: 0.6 %重庆: 0.6 %铁岭: 0.2 %铁岭: 0.2 %铜川: 0.2 %铜川: 0.2 %银川: 0.2 %银川: 0.2 %镇江: 0.2 %镇江: 0.2 %长春: 0.4 %长春: 0.4 %长沙: 1.4 %长沙: 1.4 %长治: 0.4 %长治: 0.4 %阜新: 0.2 %阜新: 0.2 %青岛: 1.0 %青岛: 1.0 %鞍山: 0.2 %鞍山: 0.2 %驻马店: 0.2 %驻马店: 0.2 %黄冈: 1.0 %黄冈: 1.0 %其他China[]上海中卫临汾丽水亳州信阳兰州北京厦门台州合肥呼和浩特商洛嘉兴大同大连天津太原宁波安康宜昌巴音郭楞广州廊坊张家口恩施成都昆明昌吉普洱朝阳杭州武汉沈阳泉州泰州洛阳济南淄博深圳湖州湛江漳州潍坊牡丹江盐城石家庄绍兴芒廷维尤苏州莆田菏泽衢州西宁西安贵阳运城重庆铁岭铜川银川镇江长春长沙长治阜新青岛鞍山驻马店黄冈Highcharts.com

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4340) PDF downloads(966) Cited by(1)

Related
Proportional views

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

doi: 10.3969/j.issn.1006-0111.2016.04.022
  • 1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China
  • 2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China
  • Received Date: 2016-04-08
  • Rev Recd Date: 2016-05-17

Abstract: Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.

ZHU Hengmei, LU Guihua, FANG Shuheng, XU Lili. Pain Management with fentanyl transdermal and morphine subcutaneous injection for the patients with advanced liver cancer pain after intervention therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 75-77. doi: 10.3969/j.issn.1006-0111.2017.01.019
Citation: CAO Yue, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 366-371. doi: 10.3969/j.issn.1006-0111.2016.04.022
shu

    HTML

Reference (22)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return